AC Immune (ACIU) Enterprise Value (2014 - 2026)
AC Immune (ACIU) posted quarterly Enterprise Value of -$95.5 billion for Q1 2026, down 58875.4% year-over-year from N/an in Q1 2025, and down 18.1% quarter-over-quarter from -$80.9 billion in Q4 2025.
AC Immune (ACIU) Enterprise Value (2014 - 2026) Analysis & Trends
AC Immune (ACIU) has reported Enterprise Value for 13 consecutive years, with -$95.5 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Enterprise Value fell 58875.4% year-over-year to -$95.5 billion; the TTM figure through Mar 2026 stood at -$95.5 billion (down 58875.4% YoY), while the FY2025 annual figure was -$78.0 billion, down 41173.1% from the prior year.
- Enterprise Value slipped to -$95.5 billion in Q1 2026 per ACIU's latest filing, from -$80.9 billion in the prior quarter.
- Across five years, Enterprise Value topped out at -$90.5 million in Q3 2023 and bottomed at -$125.6 billion in Q1 2022.
- Historically, Enterprise Value has averaged -$23.4 billion across 5 years, with a median of -$162.0 million in 2025.
- Annual changes were most pronounced in 2023 — Enterprise Value surged 99.91% — and 2026, when it slumped 58875.4%.
- AC Immune's Enterprise Value stood at -$127.2 million in 2022, then slipped by 28.41% to -$163.4 million in 2023, then decreased by 15.61% to -$188.9 million in 2024, then sank by 42714.39% to -$80.9 billion in 2025, then decreased by 18.1% to -$95.5 billion in 2026.
- Business Quant data shows ACIU's Enterprise Value at -$95.5 billion in Q1 2026, -$80.9 billion in Q4 2025, and -$135.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | AC Immune | 253.89 Mn | 253.89 Mn | - | -95.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -95.40 Mn |
| Mar 31, 2026 | -95.52 Bn |
| Dec 31, 2025 | -80.88 Bn |
| Sep 30, 2025 | -135.60 Mn |
| Jun 30, 2025 | -153.57 Mn |
| Mar 31, 2025 | -161.96 Mn |
| Dec 31, 2024 | -188.91 Mn |
| Sep 30, 2024 | -182.24 Mn |
| Jun 30, 2024 | -193.65 Mn |
| Mar 31, 2024 | -120.09 Mn |
| Dec 31, 2023 | -163.40 Mn |
| Sep 30, 2023 | -90.49 Mn |
| Jun 30, 2023 | -103.44 Mn |
| Mar 31, 2023 | -113.99 Mn |
| Dec 31, 2022 | -127.25 Mn |
| Sep 30, 2022 | -145.48 Mn |
| Jun 30, 2022 | -94.55 Bn |
| Mar 31, 2022 | -125.61 Bn |
| Dec 31, 2021 | -125.89 Bn |
| Sep 30, 2021 | -103.57 Bn |